Formulation Development

The iCELLis™ bioreactor system is an automated, single-use, fixed-bed bioreactor that provides excellent cell growth conditions for adherent cells.

Routine cell culture? Check!

For researchers who need consistent experimental outcomes, Mateo TL enables all lab members to check and document cell growth status conveniently and comfortably.

Measure confluency consistently, thereby increasing the confidence in the success of their downstream experiments.

Automated bioprinting solution for high-content screening with the BAB400 bioprinter for optimized 3D tissue and organoid workflow.

Designed for today’s assays and tomorrow’s breakthroughs—flexible detection that evolves with your science.

The SpectraMax® iD3s and iD5e Multi-Mode Microplate Readers deliver flexible, scalable solutions for absorbance, fluorescence, and luminescence assays—with advanced capabilities for evolving research needs. The iD3s reader offers a streamlined, affordable platform with a tunable monochromator and temperature control, while the iD5e reader adds enhanced detection modes including time-resolved fluorescence (TRF) and tunable fluorescence polarization (FP) and can be expanded to include TR-FRET, HTRF, BRET and western blot. Both readers support on board fluidics with optional dual injectors.

Analyzing GLP-1 receptor agonist (RA) drugs has become increasingly complex. Peptide structures, closely-related impurities, and rising demands for sensitivity, speed, and compliance are putting pressure on laboratories.

Precise optics, fluidic transfer, and assay flexibility on one integrated microplate reader.

Whether you're looking to boost performance, enhance your capabilities, or simply get consistent, high-quality results, HyClone™ peak expression medium and HyClone™ prime expression medium are the solutions for you.

Curia’s DMPK scientists deliver expert solutions for your drug discovery programs. Providing bioanalytical methods development, in vitro ADMET testing and in vivo PK and PD services that span all stages of drug discovery up to candidate selection.